Blog

Organoid Technology can be used for drug toxicity testing, efficacy evaluation, and new drug screening. Still, also it can be used to establish disease models to study genetic diseases, infectious diseases, and tumors. Medicilon will also lay out a pharmacology research platform for organoids.

Cell Gene therapy products should conduct systematic nonclinical research, assess safety risks, and verify effectiveness mechanisms so as to support relevant clinical trials and marketing.Medicilon has built a one-stop research platform for the preclinical R&D of Cell Gene therapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK.

The development and manufacturing of NCE and API are striving for simplifying and shortening timelines. Implementing QbD principles in new chemical entities (NCE) and active pharmaceutical ingredients (API) development can lead to reduced costs, faster time to market, and improved patient outcomes.

Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. Medicilon has assisted no less than ten ADC drugs to IND.

In innovative drug development, conducting toxicology studies to determine the type, dose, and mechanism of toxic response to a drug is essential to deciding on a drug’s safety and efficacy, developing safe drug use strategies, and avoiding unnecessary drug toxicities.

October 29th, 2022, is the seventeenth “World Stroke Day.” “World Stroke Day” was established by the World Stroke Organization (World Stroke Organization) to call for strengthening public awareness of stroke globally.